JP6158180B2 - 乳がんの処置 - Google Patents

乳がんの処置 Download PDF

Info

Publication number
JP6158180B2
JP6158180B2 JP2014523048A JP2014523048A JP6158180B2 JP 6158180 B2 JP6158180 B2 JP 6158180B2 JP 2014523048 A JP2014523048 A JP 2014523048A JP 2014523048 A JP2014523048 A JP 2014523048A JP 6158180 B2 JP6158180 B2 JP 6158180B2
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heterocyclic
alkenyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014523048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524934A (ja
JP2014524934A5 (cg-RX-API-DMAC7.html
Inventor
アンドリュー エー． プロッター，
アンドリュー エー． プロッター，
ジェニファー リッチャー，
ジェニファー リッチャー，
ドーン コックレン，
ドーン コックレン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6158180(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of JP2014524934A publication Critical patent/JP2014524934A/ja
Publication of JP2014524934A5 publication Critical patent/JP2014524934A5/ja
Application granted granted Critical
Publication of JP6158180B2 publication Critical patent/JP6158180B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014523048A 2011-07-29 2012-07-27 乳がんの処置 Active JP6158180B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
US61/513,361 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017072819A Division JP2017141269A (ja) 2011-07-29 2017-03-31 乳がんの処置

Publications (3)

Publication Number Publication Date
JP2014524934A JP2014524934A (ja) 2014-09-25
JP2014524934A5 JP2014524934A5 (cg-RX-API-DMAC7.html) 2015-08-27
JP6158180B2 true JP6158180B2 (ja) 2017-07-05

Family

ID=48192564

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014523048A Active JP6158180B2 (ja) 2011-07-29 2012-07-27 乳がんの処置
JP2017072819A Pending JP2017141269A (ja) 2011-07-29 2017-03-31 乳がんの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017072819A Pending JP2017141269A (ja) 2011-07-29 2017-03-31 乳がんの処置

Country Status (18)

Country Link
US (4) US9517229B2 (cg-RX-API-DMAC7.html)
EP (4) EP2739153B1 (cg-RX-API-DMAC7.html)
JP (2) JP6158180B2 (cg-RX-API-DMAC7.html)
KR (1) KR101923250B1 (cg-RX-API-DMAC7.html)
CN (1) CN103997894B (cg-RX-API-DMAC7.html)
BR (1) BR112014002200A2 (cg-RX-API-DMAC7.html)
CA (1) CA2843417C (cg-RX-API-DMAC7.html)
CY (1) CY1121038T1 (cg-RX-API-DMAC7.html)
DK (1) DK2739153T3 (cg-RX-API-DMAC7.html)
EA (1) EA028452B1 (cg-RX-API-DMAC7.html)
ES (1) ES2696074T3 (cg-RX-API-DMAC7.html)
HU (1) HUE040524T2 (cg-RX-API-DMAC7.html)
MX (1) MX359664B (cg-RX-API-DMAC7.html)
PH (1) PH12014500248B1 (cg-RX-API-DMAC7.html)
PL (1) PL2739153T3 (cg-RX-API-DMAC7.html)
PT (1) PT2739153T (cg-RX-API-DMAC7.html)
SI (1) SI2739153T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013066440A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141269A (ja) * 2011-07-29 2017-08-17 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
LT3305285T (lt) 2012-09-26 2020-12-10 Aragon Pharmaceuticals, Inc. Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
AU2013404949B2 (en) * 2013-11-07 2018-10-18 Deciphera Pharmaceuticals, Llc Methods for inhibiting TIE2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
EP3148336B1 (en) 2014-05-28 2019-10-02 Eisai R&D Management Co., Ltd. Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US10736845B2 (en) 2015-03-03 2020-08-11 Cureport Inc. Dual loaded liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
KR102795129B1 (ko) 2017-06-22 2025-04-15 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
BR112020015581A2 (pt) 2018-01-31 2021-02-02 Deciphera Pharmaceuticals, Llc terapia de combinação para o tratamento de tumores estromais gastrointestinais
SG11202007287XA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of mastocytosis
WO2020113088A1 (en) * 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
CN119950433A (zh) 2019-12-30 2025-05-09 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101332924B1 (ko) * 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
SI3412290T1 (sl) 2006-03-27 2021-09-30 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
CN102755318B (zh) 2006-03-29 2014-09-10 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
PE20121470A1 (es) * 2007-10-26 2012-11-18 Univ California Compuestos de diarilhidantoina como antagonistas del receptor de androgeno
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) * 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
JP2012518661A (ja) 2009-02-24 2012-08-16 メディベイション プロステイト セラピューティクス， インコーポレイテッド 特定のジアリールヒダントインおよびジアリールチオヒダントイン化合物
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8507195B2 (en) * 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
EP2685988A4 (en) 2011-03-15 2014-08-20 Univ North Carolina Methods of treating breast cancer with anthracycline therapy
EP2739153B1 (en) * 2011-07-29 2018-08-22 Medivation Prostate Therapeutics LLC Treatment of breast cancer
WO2013082440A2 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
AU2013306380A1 (en) 2012-08-23 2015-03-05 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
US20140154681A1 (en) 2012-11-12 2014-06-05 Nanostring Technologies, Inc. Methods to Predict Breast Cancer Outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
MX2017007707A (es) 2014-12-12 2018-03-06 Medivation Prostate Therapeutics Llc Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141269A (ja) * 2011-07-29 2017-08-17 メディベイション プロステイト セラピューティクス， インコーポレイテッド 乳がんの処置

Also Published As

Publication number Publication date
PT2739153T (pt) 2018-11-28
EP3430907A1 (en) 2019-01-23
CA2843417C (en) 2018-08-21
PH12014500248B1 (en) 2018-08-31
KR20140107174A (ko) 2014-09-04
CY1121038T1 (el) 2019-12-11
US20140296312A1 (en) 2014-10-02
JP2014524934A (ja) 2014-09-25
PL2739153T3 (pl) 2019-04-30
HUE040524T2 (hu) 2019-03-28
HK1201413A1 (en) 2015-09-04
WO2013066440A1 (en) 2013-05-10
US20170087132A1 (en) 2017-03-30
US9517229B2 (en) 2016-12-13
PH12014500248A1 (en) 2014-03-17
WO2013066440A9 (en) 2013-07-18
JP2017141269A (ja) 2017-08-17
EP3791724A1 (en) 2021-03-17
BR112014002200A2 (pt) 2017-03-07
EP2739153B1 (en) 2018-08-22
ES2696074T3 (es) 2019-01-14
CN103997894B (zh) 2016-08-24
MX359664B (es) 2018-10-05
EA028452B1 (ru) 2017-11-30
KR101923250B1 (ko) 2018-11-28
CA2843417A1 (en) 2013-05-10
DK2739153T3 (en) 2018-12-03
EP3610731A1 (en) 2020-02-19
US10111861B2 (en) 2018-10-30
HK1198867A1 (en) 2015-06-19
EA201400178A1 (ru) 2014-11-28
CN103997894A (zh) 2014-08-20
SI2739153T1 (sl) 2018-12-31
EP2739153A4 (en) 2015-03-11
US20210069154A1 (en) 2021-03-11
EP2739153A1 (en) 2014-06-11
MX2014001218A (es) 2014-08-22
US20190262315A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
JP6158180B2 (ja) 乳がんの処置
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
CN101370497A (zh) 利用parp抑制剂的联合疗法
EP3120849A1 (en) Cancer stem cell proliferation inhibitor and intracellular active oxygen accumulation inducer
JP6748704B2 (ja) 抗癌治療剤
WO2012173677A2 (en) Anticancer therapeutic agents
AU2012290979A1 (en) Method for treating cancer by combined use of medicinal agents
TW201343169A (zh) 使用奧諾拉（ａｕｒｏｒａ）激酶抑制劑治療癌症的方法
JP2022527451A (ja) Ｐｋｍ２モジュレーターおよびその使用方法
CN108187055B (zh) 一种具有协同增效作用的抗癌组合物
HK1201413B (en) Treatment of breast cancer
AU2014290012B2 (en) Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
HK40058784B (en) (n-(2-((2-benzylphenyl)amino)-2-oxoethyl)-l-naphthamide) as anticancer therapeutic agent
HK1198867B (en) Treatment of breast cancer
CN101198253A (zh) 治疗癌症的组合、方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160502

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160817

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160817

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161028

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170331

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170607

R150 Certificate of patent or registration of utility model

Ref document number: 6158180

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250